vs
Side-by-side financial comparison of Axsome Therapeutics, Inc. (AXSM) and VICOR CORP (VICR). Click either name above to swap in a different company.
Axsome Therapeutics, Inc. is the larger business by last-quarter revenue ($196.0M vs $113.0M, roughly 1.7× VICOR CORP). VICOR CORP runs the higher net margin — 18.3% vs -14.6%, a 32.9% gap on every dollar of revenue. On growth, Axsome Therapeutics, Inc. posted the faster year-over-year revenue change (65.0% vs 20.2%). Over the past eight quarters, Axsome Therapeutics, Inc.'s revenue compounded faster (61.7% CAGR vs 14.7%).
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
Vicor Corporation is a manufacturer of power modules headquartered in Andover, Massachusetts.
AXSM vs VICR — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $196.0M | $113.0M |
| Net Profit | $-28.6M | $20.7M |
| Gross Margin | — | — |
| Operating Margin | -13.8% | 59.7% |
| Net Margin | -14.6% | 18.3% |
| Revenue YoY | 65.0% | 20.2% |
| Net Profit YoY | 61.9% | 713.9% |
| EPS (diluted) | $-0.55 | $0.44 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $113.0M | ||
| Q4 25 | $196.0M | $107.3M | ||
| Q3 25 | $171.0M | $110.4M | ||
| Q2 25 | $150.0M | $96.0M | ||
| Q1 25 | $121.5M | $94.0M | ||
| Q4 24 | $118.8M | $96.2M | ||
| Q3 24 | $104.8M | $93.2M | ||
| Q2 24 | $87.2M | $85.9M |
| Q1 26 | — | $20.7M | ||
| Q4 25 | $-28.6M | $46.5M | ||
| Q3 25 | $-47.2M | $28.3M | ||
| Q2 25 | $-48.0M | $41.2M | ||
| Q1 25 | $-59.4M | $2.5M | ||
| Q4 24 | $-74.9M | $10.2M | ||
| Q3 24 | $-64.6M | $11.6M | ||
| Q2 24 | $-79.3M | $-1.2M |
| Q1 26 | — | — | ||
| Q4 25 | — | 55.4% | ||
| Q3 25 | — | 57.5% | ||
| Q2 25 | — | 95.9% | ||
| Q1 25 | — | 47.2% | ||
| Q4 24 | — | 52.4% | ||
| Q3 24 | — | 49.1% | ||
| Q2 24 | — | 49.8% |
| Q1 26 | — | 59.7% | ||
| Q4 25 | -13.8% | 14.6% | ||
| Q3 25 | -27.0% | 18.9% | ||
| Q2 25 | -24.5% | 47.3% | ||
| Q1 25 | -46.9% | -0.2% | ||
| Q4 24 | -61.1% | 9.6% | ||
| Q3 24 | -59.8% | 5.8% | ||
| Q2 24 | -89.5% | 0.2% |
| Q1 26 | — | 18.3% | ||
| Q4 25 | -14.6% | 43.4% | ||
| Q3 25 | -27.6% | 25.6% | ||
| Q2 25 | -32.0% | 42.9% | ||
| Q1 25 | -48.9% | 2.7% | ||
| Q4 24 | -63.1% | 10.7% | ||
| Q3 24 | -61.7% | 12.4% | ||
| Q2 24 | -91.0% | -1.4% |
| Q1 26 | — | $0.44 | ||
| Q4 25 | $-0.55 | $1.01 | ||
| Q3 25 | $-0.94 | $0.63 | ||
| Q2 25 | $-0.97 | $0.91 | ||
| Q1 25 | $-1.22 | $0.06 | ||
| Q4 24 | $-1.54 | $0.24 | ||
| Q3 24 | $-1.34 | $0.26 | ||
| Q2 24 | $-1.67 | $-0.03 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $322.9M | $404.2M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $88.3M | $754.1M |
| Total Assets | $689.8M | $804.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $404.2M | ||
| Q4 25 | $322.9M | $402.8M | ||
| Q3 25 | $325.3M | $362.4M | ||
| Q2 25 | $303.0M | $338.5M | ||
| Q1 25 | $300.9M | $296.1M | ||
| Q4 24 | $315.4M | $277.3M | ||
| Q3 24 | $327.3M | $267.6M | ||
| Q2 24 | $315.7M | $251.9M |
| Q1 26 | — | $754.1M | ||
| Q4 25 | $88.3M | $711.6M | ||
| Q3 25 | $73.7M | $630.1M | ||
| Q2 25 | $73.1M | $608.6M | ||
| Q1 25 | $53.2M | $580.3M | ||
| Q4 24 | $57.0M | $570.1M | ||
| Q3 24 | $92.9M | $554.6M | ||
| Q2 24 | $102.9M | $537.2M |
| Q1 26 | — | $804.9M | ||
| Q4 25 | $689.8M | $785.8M | ||
| Q3 25 | $669.3M | $710.2M | ||
| Q2 25 | $639.8M | $693.5M | ||
| Q1 25 | $596.7M | $665.0M | ||
| Q4 24 | $568.5M | $641.1M | ||
| Q3 24 | $561.5M | $632.8M | ||
| Q2 24 | $548.2M | $613.2M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-18.7M | — |
| Free Cash FlowOCF − Capex | $-18.7M | — |
| FCF MarginFCF / Revenue | -9.6% | — |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-93.9M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-18.7M | $15.7M | ||
| Q3 25 | $1.0M | $38.5M | ||
| Q2 25 | $-32.4M | $65.2M | ||
| Q1 25 | $-43.4M | $20.1M | ||
| Q4 24 | $-26.2M | $10.1M | ||
| Q3 24 | $-18.6M | $22.6M | ||
| Q2 24 | $-30.1M | $15.6M |
| Q1 26 | — | — | ||
| Q4 25 | $-18.7M | $10.2M | ||
| Q3 25 | $988.0K | $34.5M | ||
| Q2 25 | $-32.4M | $59.0M | ||
| Q1 25 | $-43.7M | $15.6M | ||
| Q4 24 | $-26.2M | $8.4M | ||
| Q3 24 | $-18.7M | $14.1M | ||
| Q2 24 | $-30.2M | $9.4M |
| Q1 26 | — | — | ||
| Q4 25 | -9.6% | 9.5% | ||
| Q3 25 | 0.6% | 31.2% | ||
| Q2 25 | -21.6% | 61.5% | ||
| Q1 25 | -36.0% | 16.6% | ||
| Q4 24 | -22.1% | 8.7% | ||
| Q3 24 | -17.9% | 15.2% | ||
| Q2 24 | -34.6% | 11.0% |
| Q1 26 | — | — | ||
| Q4 25 | 0.0% | 5.2% | ||
| Q3 25 | 0.0% | 3.6% | ||
| Q2 25 | 0.0% | 6.5% | ||
| Q1 25 | 0.3% | 4.8% | ||
| Q4 24 | 0.0% | 1.8% | ||
| Q3 24 | 0.1% | 9.1% | ||
| Q2 24 | 0.1% | 7.2% |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.34× | ||
| Q3 25 | — | 1.36× | ||
| Q2 25 | — | 1.58× | ||
| Q1 25 | — | 7.93× | ||
| Q4 24 | — | 0.99× | ||
| Q3 24 | — | 1.95× | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AXSM
Segment breakdown not available.
VICR
| Product revenue | $98.0M | 87% |
| Royalty revenue | $15.0M | 13% |
